Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial

By afschroeder • October 24, 2025

Hecht JR, Park YS, Tabernero J, Lee MA, Lee S, Virgili AC, Van den Eynde M, Fontana E, Fakih M, Asghari G, So J, Stein A, Dubreuil O, Bodnar L, He CS, Wang G, Smith R, Eng C, Saeed A; STELLAR-303 study investigators. Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial. Lancet. 2025 Oct 20:S0140-6736(25)02025-2. doi: 10.1016/S0140-6736(25)02025-2. Epub ahead of print. PMID: 41130252.

Tags: Hematology/Oncology, Publications

Do All Breast Cancer Survivors Need to See a Cardiologist?

Ganz PA, Yang EH. Do All Breast Cancer Survivors Need to See a Cardiologist? JAMA Oncol. 2025 Oct 23. doi: 10.1001/jamaoncol.2025.4141. Epub ahead of print.[...]

Analyses of adverse events and patient-reported outcomes with the toxicity index in cancer clinical trials

Gresham G, Henry NL, Bandos H, Calsavara VF, Cecchini RS, Diniz MA, Hays RD, Luu M, Kim S, Rogatko A, Yothers G, Ganz PA, Tighiouart[...]

Anti-VEGF neutralizing antibody delays osteomucosal healing by reducing collagen formation in mice

Bae EB, Kim MY, Ji S, Cho IW, Kim SY, Esmaeili M, Baik SS, Kim S, Tetradis S, Park NH, Gwack Y, Kim RH. Anti-VEGF[...]